Henoch-Schönlein purpura in a 6-year-old boy after initial COVID-19 vaccination

•Henoch-Schönlein purpura onset after mRNA COVID-19 first vaccine dose in a child.•Uncommon sign of a probable underlying autoimmune/inflammatory condition.•Possibility of exacerbation following vaccination with a mRNA-based vaccine. The COVID-19 pandemic has significantly impacted global health, and the widespread immunization of adults against SARS-CoV-2 has played a pivotal role in altering the course of the disease. While COVID-19 vaccine adverse events are generally uncommon and mild, the recent vaccination of the pediatric population has emphasized the need for vigilance and reporting of potential side effects. In this case report, we present a 6-year-old boy who developed Henoch-Schönlein purpura following the administration of the first dose of Pfizer-BioNTech BNT16B2b2 mRNA COVID-19 vaccine, making it the earliest reported case of such an adverse event. Our report highlights the importance of continued monitoring and reporting of adverse events in pediatric patients receiving the COVID-19 vaccine, as well as the need for prompt diagnosis and management of potential vaccine-related complications.